Replies to post #432 on Armata Pharmaceuticals, Inc. (ARMP)

[Rogerthat1]

Agreed. But why Wendy. She is the coo. Not a cmo? Hmm..

[Rogerthat1]

Wendy probably has a broader role than just an acting COO imo.

Background on Wendy:

Ms. Wendy S. Johnson has been Interim Chief Operating Officer of AmpliPhi Biosciences Corporation since September 2014 and serves as its Managing Director of Gemini Advisors. Ms. Johnson serves as the President and Chief Executive Officer of Palkion Inc. She was a Venture Partner at ProQuest Investments. She joined ProQuest in 2005 and has broad experience in licensing, strategy and corporate development. She was the Founder, President and Chief Executive Officer at Aires Pharmaceuticals, Inc. She has a broad range of experience in the regulatory and pharmaceutical industry and has successfully licensed multiple value-generating therapeutic products, negotiated acquisitions and established several international strategic alliances. She also has additional experience with device, diagnostic, and drug discovery and development and regulatory affairs. Previously, she joined Salmedix Inc. as a Senior Vice President of Corporate Development in April 2001, where she led the effort to license their lead cancer therapeutic. Earlier, she served as the Vice President of Business Development at Women First Healthcare, Inc. from July 1998 to July 2000 and a Vice President of Corporate Development and Operations at Prizm Pharmaceuticals, from July 1994 to July 1998. She served as the Vice President of Business Development and Regulatory Affairs at Cytel Corporation from July 1990 to June 1994. She also served at Symbiotics Corp. and Murex Corp. She also served as an Assistant Director in the Center for Devices and Radiological Health in the Food and Drug Administration. She has been a Director of AmpliPhi Biosciences Corporation since May 19, 2014. She has been a Member of Supervisory Board at Morphosys AG since May 8, 2015. Ms. Johnson received an M.B.A. from Loyola University, an M.S. in Clinical Microbiology from Hahnemann Medical School and a B.S. degree in Microbiology from the University of Maryland.

Link: http://www.bloomberg.com/research/stocks/people/person.asp?personId=233442&privcapId=35106

[Rogerthat1]

You were correct amigo.

Milestone Cash Payment Payment Timing
Produce one clinical study report by December 31, 2016 that is reasonably acceptable to the Company

From the filing: https://www.sec.gov/Archives/edgar/data/921114/000114420416126054/v449659_ex99-1.htm